Lung Cancer Genomic Testing Market - Global Forecast 2025-2030

The Lung Cancer Genomic Testing Market size was estimated at USD 1.07 billion in 2024 and expected to reach USD 1.16 billion in 2025, at a CAGR 8.35% to reach USD 1.73 billion by 2030.

Lung cancer remains one of the most formidable challenges in oncology, with more people in the United States dying from this disease than from any other type of cancer. According to the Centers for Disease Control and Prevention, 218,893 new lung cancers were reported in the United States in 2022 and 131,584 deaths occurred in 2023, underscoring the urgent need for improved diagnostic and treatment strategies. The high mortality rate is largely a consequence of late-stage diagnoses, as nearly half of lung cancers are detected after the disease has already metastasized, when curative options are limited and survival rates drop significantly.

In response to these challenges, the field has seen a rapid shift toward integrating genomic testing into clinical workflows. By analyzing tumor DNA through techniques such as next-generation sequencing and liquid biopsy, clinicians can identify actionable mutations that guide targeted therapies and immunotherapies. A study assessing non–small cell lung cancer patients found that comprehensive genomic profiling via next-generation sequencing panels, which include at least 50 genes, doubled clinical trial enrollment and improved treatment outcomes by enabling timely selection of appropriate therapies. These advances reflect a broader move toward precision medicine, where genomic insights drive individualized care plans and hold promise for improving survival and quality of life.

The landscape of lung cancer genomic testing is being reshaped by innovations that amplify both the scope and speed of analysis. Next-generation sequencing (NGS) technologies now offer broad panels capable of parallel analysis of multiple gene alterations, making it possible to detect rare mutations that drive cancer growth. A single-center study demonstrated that 26% of patients had actionable mutations identified only through NGS that were missed by non-NGS testing strategies, emphasizing the potential of these platforms to uncover clinically relevant targets. As the number of recommended biomarkers continues to grow, clinical laboratories are adopting NGS systems that balance comprehensiveness with minimal tissue requirements, enabling efficient workflows even in cases where biopsy samples are limited.

Beyond sequencing, the integration of artificial intelligence and multi-omics approaches is unlocking deeper insights into tumor biology. AI-driven analytics embedded in reporting platforms reduce interpretation time and improve consistency, as evidenced by substantial R&D investments from leading instrument suppliers aimed at precision medicine tools that simplify genomic data interpretation. Concurrently, long-read sequencing technologies and mass spectrometry workflows are emerging to complement genomic assays with structural variant detection and proteomic data. These paradigm-shifting innovations are democratizing access to complex molecular profiles, offering clinicians actionable intelligence faster than ever before.

In 2025, the United States implemented sweeping tariffs on imported biopharmaceutical components and laboratory consumables, with rates reaching up to 30% on life science tools from China and 20% on instruments from the European Union. Biogen’s announcement of a $2 billion investment in North Carolina manufacturing facilities exemplifies the industry’s pivot toward reshoring key operations in anticipation of escalating import levies. These measures aim to mitigate exposure to unpredictable trade policies but also introduce new challenges related to capacity and capital deployment.

The repercussions extend beyond manufacturing footprint expansions. Major pharmaceutical companies have struck record licensing deals with Chinese biotech firms, reflecting a strategy to secure early-stage innovations even as U.S. tariffs loom over finished products. Simultaneously, a survey by the Biotechnology Innovation Organization revealed that nearly 90% of U.S. biotech companies rely on imported components for at least half of their FDA-approved products, and 94% anticipate significant cost increases if tariffs are enforced on European imports. This intense global integration of supply chains means that testing providers must now balance cost pressures with the need to maintain rapid turnaround times.

Amid this uncertainty, life science tools manufacturers face margin compression as cost of goods sold rises. Analysts project that tariffs could increase COGS by an average of 2% across the industry, with certain firms experiencing even larger impacts, leading to higher prices for end users and further complicating the economics of genomic testing. These dynamics are forcing stakeholders to reevaluate sourcing strategies, accelerate inventory buffering, and explore alternative suppliers outside tariff-impacted regions to sustain the momentum of personalized cancer care.

The technology spectrum driving lung cancer genomic testing spans traditional and cutting-edge modalities, from fluorescence in situ hybridization and microarray analysis to next-generation sequencing, real-time polymerase chain reaction, and classic Sanger sequencing. Among these, next-generation sequencing stands out for its ability to simultaneously profile multiple gene targets, with targeted panels remaining widely adopted for hotspot mutation detection and whole-exome or whole-genome sequencing gaining traction for comprehensive mutational landscapes. As sequencing costs decrease and platforms require ever-smaller sample inputs, laboratories are integrating NGS workflows to keep pace with the growing roster of actionable biomarkers.

When considering test types, liquid biopsy and tissue biopsy carve distinct yet complementary niches. Circulating tumor DNA assays excel at minimally invasive sampling and dynamic monitoring of tumor evolution, while circulating tumor cell enrichment offers opportunities for morphological and additional molecular characterization. Conversely, fine-needle aspiration and standard tissue sectioning remain critical for histopathological assessment and initial diagnostic confirmation. Both approaches feed into broader applications such as companion diagnostics, predictive testing to anticipate therapeutic response, prognostic assessments that inform patient counseling, and treatment monitoring to detect emerging resistance patterns in real time.

Across clinical use cases, companion diagnostics sustain the highest demand as precision therapies become increasingly mutation-specific, while predictive testing supports early risk stratification and preventive strategies. Prognostic assays offer insights into disease trajectory, guiding care pathways and end-of-life planning. Treatment monitoring through serial sampling ensures that therapeutic efficacy is tracked and adjustments are made swiftly to counter drug resistance, a critical factor in extending patient survival.

Underlying these modalities, a diverse end user landscape drives innovation and adoption. Academic and research institutes pioneer novel assays and validate emerging biomarkers, whereas hospitals and diagnostic laboratories translate these discoveries into routine patient care. Pharmaceutical and biotechnology companies leverage genomic testing for drug development, clinical trial enrollment, and companion diagnostic co-development, forging partnerships that accelerate time to market for targeted therapies.

The Americas region, led by the United States, commands leadership in lung cancer genomic testing owing to robust research funding, comprehensive reimbursement structures, and a dense network of clinical trial sites. North America’s dominance in liquid biopsy for early cancer detection, which accounted for over half of global adoption in 2023, underscores the region’s appetite for non-invasive diagnostic innovation and its supportive regulatory environment. This momentum is fueled by strategic collaborations between academic centers and industry, accelerating the translation of genomic insights into clinical practice.

In Europe, the Middle East, and Africa, Western European nations drive uptake through favorable health technology assessments and early adoption of personalized medicine guidelines. England’s National Health Service has pioneered the implementation of a groundbreaking liquid biopsy blood test for lung cancer, demonstrating the potential to reduce time to targeted therapy decisions by over two weeks compared to traditional approaches. Meanwhile, emerging markets across the Middle East and parts of Africa are launching precision oncology initiatives, often in partnership with international organizations, to build local capacity for genomic testing and expand access beyond metropolitan centers.

Asia-Pacific presents a dynamic landscape shaped by significant investments in domestic sequencing infrastructure and a growing cadre of biotech innovators. China’s rapid ascent in biotech has catalyzed licensing deals with multinational pharmaceutical companies and fueled the development of indigenous NGS platforms. Government incentives in Japan, South Korea, and Australia further support the integration of genomic testing into national cancer control programs. These regional efforts, combined with tailored reimbursement policies in key markets, position Asia-Pacific as a burgeoning hub for next-generation diagnostics and translational research.

Thermo Fisher Scientific has reinforced its leadership with the CE-IVD marked Ion Torrent Genexus Dx Integrated Sequencer, delivering an automated NGS platform capable of processing comprehensive panels in as little as one day. This innovation streamlines laboratory workflows by combining sample prep and sequencing into a single instrument, accelerating turnaround for actionable results. Meanwhile, Illumina’s expanded clinical oncology portfolio, including the FDA-approved TruSight Oncology Comprehensive and Pillar oncoReveal CDx panels, offers in vitro diagnostic kits designed for seamless integration into community and academic laboratories, empowering clinicians to match patients with precision therapies swiftly.

Guardant Health has emerged as a pioneer in liquid biopsy, with its circulating tumor DNA assays becoming instrumental in companion diagnostic programs and resistance monitoring studies. The company’s strategic partnerships with pharmaceutical developers have positioned its tests at the forefront of clinical trial biomarker screening. Qiagen and Agilent Technologies continue to strengthen their PCR-based and sample preparation workflows, ensuring high sensitivity for single-gene analyses while supporting laboratories in low-resource settings.

Instrument suppliers such as Pacific Biosciences and Oxford Nanopore are gaining traction with long-read sequencing solutions that capture structural variants and complex rearrangements, complementing short-read NGS assays. Bio-Rad Laboratories has expanded its bioinformatics offerings to support laboratories lacking in-house computational resources, embedding AI-driven analytics into reporting platforms to provide consistent, actionable interpretations of high-throughput data.

Leaders in the lung cancer genomic testing sector should prioritize strengthening supply chain resilience by diversifying sourcing and forging alliances with domestic CDMOs, thus mitigating the impact of trade policy volatility. Engaging proactively with policymakers to shape equitable tariff frameworks and secure temporary tariff exemptions for critical reagents will help sustain affordable access to testing components, as advocated by a recent survey from the Biotechnology Innovation Organization.

In tandem, companies must invest in integrated digital ecosystems that unify NGS data, liquid biopsy results, and clinical insights, driving seamless interoperability across hospital information systems and research databases. Accelerating the adoption of AI-powered analytics and multi-omics integration will unlock deeper molecular insights, enabling developers to offer next-generation assays that address emerging biomarkers while maintaining streamlined workflows and cost efficiency.

Furthermore, stakeholders should build robust evidence through real-world evidence studies and clinical validation trials to demonstrate the clinical utility and economic value of comprehensive genomic profiling. Collaborations with academic institutions and payers can facilitate coverage agreements and bolster the case for reimbursement, ensuring that precision oncology becomes accessible to a broader patient population. Clear communication of these outcomes to healthcare providers and patient advocacy groups will accelerate adoption and reinforce the value proposition of genomic testing.

This research combines exhaustive secondary analysis of epidemiological data from federal sources such as the CDC’s United States Cancer Statistics with peer-reviewed clinical studies published in leading oncology journals. Key insights on technological advancements and industry dynamics were corroborated through a review of press releases and filings from major instrument suppliers, alongside membership survey data from the Biotechnology Innovation Organization.

Primary data collection included expert interviews with clinical oncologists, molecular pathologists, and laboratory directors, providing context to emerging applications of next-generation sequencing and liquid biopsy. Quantitative metrics were triangulated across multiple datasets to validate trends in adoption, while qualitative feedback highlighted barriers and enablers for clinical implementation.

Rigorous data validation protocols ensured consistency and reliability, leveraging cross-referencing between government reports, scientific literature, and in-depth case studies. Analytical frameworks were designed to identify transformative shifts, assess trade policy impacts, and map segmentation insights, yielding a comprehensive overview of the lung cancer genomic testing landscape.

In summary, genomic testing has emerged as an indispensable pillar of modern lung cancer care, empowering clinicians to shift from one-size-fits-all approaches toward highly personalized treatment pathways. Technological advances in next-generation sequencing and liquid biopsy have set a new standard, while AI-driven analytics and multi-omics integration promise to further refine diagnostic accuracy and therapeutic matching.

However, external factors such as the United States’ 2025 tariff policies underscore the importance of supply chain resilience and proactive policy engagement to safeguard access to critical testing components. The nuanced segmentation across technologies, test types, applications, and end users reveals pockets of opportunity, especially as diverse regional markets continue to embrace precision oncology at different paces.

Key industry players are driving the market forward through strategic innovations and partnerships, yet sustained progress will depend on collaborative efforts across stakeholders to demonstrate clinical utility, secure equitable reimbursement, and deliver actionable insights to patients and providers alike. This evolving landscape demands agile strategies and evidence-based approaches to ensure that genomic testing realizes its full potential in improving outcomes for lung cancer patients.

To explore the most nuanced insights and leverage cutting-edge data in your strategic planning, reach out to Ketan Rohom, Associate Director of Sales & Marketing. He can guide you through the comprehensive capabilities of our lung cancer genomic testing report and ensure you obtain the tailored intelligence needed to outpace competitors. Engage with an expert who understands both the science and the market dynamics to inform your next steps.

Secure your copy of the full report today and transform the way your organization approaches genomic testing in oncology. Ketan Rohom will provide you with a detailed overview of the report’s structure, methodology, and exclusive findings, helping you make an informed decision that aligns with your business objectives.